NO20091239L - Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav - Google Patents

Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO20091239L
NO20091239L NO20091239A NO20091239A NO20091239L NO 20091239 L NO20091239 L NO 20091239L NO 20091239 A NO20091239 A NO 20091239A NO 20091239 A NO20091239 A NO 20091239A NO 20091239 L NO20091239 L NO 20091239L
Authority
NO
Norway
Prior art keywords
derivatives
conjugates
disorazoles
binding molecules
cell binding
Prior art date
Application number
NO20091239A
Other languages
English (en)
Inventor
Eckhard Guenther
Olaf Schaefer
Michael Teifel
Klaus Paulini
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06018750A external-priority patent/EP1900742A1/en
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of NO20091239L publication Critical patent/NO20091239L/no

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer konjugater av disorazoler og deres derivater med cellebindingsmolekyler, slike som peptider, proteiner, hormoner, blodprotemer og antistoffer. Foreliggende oppfinnelse tilveiebringer videre nye disorazolderivater og fremgangsmåter for fremstilling av slike konjugater og disorazolderivater. Disse forbindelsene kan anvendes som medikamenter for behandling av fysiologiske og/eller patofysiologiske tilstander hos pattedyr, særlig for behandling av forskjellige tumorer.
NO20091239A 2006-09-06 2009-03-25 Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav NO20091239L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84235706P 2006-09-06 2006-09-06
EP06018750A EP1900742A1 (en) 2006-09-07 2006-09-07 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
PCT/EP2007/059310 WO2008028934A1 (en) 2006-09-06 2007-09-06 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof

Publications (1)

Publication Number Publication Date
NO20091239L true NO20091239L (no) 2009-06-10

Family

ID=41706619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091239A NO20091239L (no) 2006-09-06 2009-03-25 Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav

Country Status (5)

Country Link
JP (1) JP5340155B2 (no)
HK (1) HK1134812A1 (no)
HR (1) HRP20160631T1 (no)
IL (1) IL197127A (no)
NO (1) NO20091239L (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877202B2 (en) * 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
BR0313789A (pt) * 2002-08-24 2005-07-05 Zentaris Gmbh Medicamento contendo disorazóis e seus derivados para o tratamento de doenças tumorais malignas e benignas
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
EP1743897A1 (en) * 2005-07-15 2007-01-17 Gesellschaft für Biotechnologische Forschung mbH Biologically active compounds obtainable from Sorangium cellulosum

Also Published As

Publication number Publication date
HK1134812A1 (en) 2010-05-14
JP2010502673A (ja) 2010-01-28
IL197127A (en) 2016-06-30
HRP20160631T1 (hr) 2016-07-15
JP5340155B2 (ja) 2013-11-13
IL197127A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
MX2013002379A (es) Moleculas de union a vegf.
ATE473438T1 (de) Zuführung von molekülen an eine lipiddoppelschicht
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
ATE537188T1 (de) Serumalbuminbindende proteine
EA201200548A1 (ru) Биспецифические связывающие молекулы для антиангиогенезной терапии
TR201908638T4 (tr) Ang2 bağlayıcı moleküller.
EA200601946A3 (ru) Антитела, связывающиеся с белками steap-1, и их производные
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
CL2008003357A1 (es) Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion.
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
WO2014102299A3 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2008143812A3 (en) Biologic devices for hemostasis
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
WO2009095452A8 (en) Crystal structure of the atpase domain of proteins of the hsp70 family
NO20091239L (no) Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application